Romosozumab Efficacy in Postmenopausal Women With No Prior Fracture Who Fulfill Criteria for Very High Fracture Risk.

Michael R McClung,Donald Betah,Cynthia Deignan,Yifei Shi,Jen Timoshanko,Felicia Cosman

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists（2023）

引用 0|浏览7

暂无评分

摘要

Romosozumab significantly reduced vertebral, clinical, and nonvertebral fracture risk and increased BMD more than placebo in women at very high fracture risk.

查看译文

关键词

American Association of Clinical Endocrinology (AACE),bone mineral density (BMD),osteoporosis,very high fracture risk (VHFR),treatment sequence

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要